Preview Mode Links will not work in preview mode

The Retina Channel Podcast


Sep 2, 2019

Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD. 

Full reference: 

Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017